Lymphocytes as cellular vehicles for gene therapy in mouse and man

Kenneth Culver, Kenneth Cornetta, Rick Morgan, Shoshana Morecki, Paul Aebersold, Attan Kasid, Michael Lotze, Steven A. Rosenberg, W. French Anderson, R. Michael Blaese

Research output: Contribution to journalArticle

116 Citations (Scopus)

Abstract

The application of bone marrow gene therapy has been stalled by the inability to achieve stable high-level gene transfer and expression in the totipotent stem cells. We show that retroviral vectors can stably introduce genes into antigen-specific murine and human T lymphocytes in culture. Murine helper T cells were transduced with the retroviral vector SAX to express both neomycin-resistance and human adenosine deaminase genes. These cells were expanded in culture and selected for expression of neomycin resistance with G418. The gene insertion, selection, and culture expansion did not alter antigen specificity or growth characteristics of the T cells in vitro. To determine if cultured T cells might be used for gene therapy, their persistence and continued expression of the introduced genes was evaluated in nude mice transplanted with the SAX-transduced T cells. G418-resistant cells could be readily recovered from the spleens of recipients of transduced T cells for several months. In addition, recovered cells continued to produce human adenosine deaminase. Based on these observations, we studied cultured human tumor-infiltrating lymphocytes as a candidate cell for a trial of gene transfer in man. Exponential cultures of interieukin-2-stimulated tumor-infiltrating lymphocytes were efficiently transduced with the neomycin-resistance gene using the retroviral vector N2. Gene insertion and subsequent G418 selection did not substantially alter the growth characteristics, interleukin 2 dependence, membrane phenotype, or cytotoxicity profile of the transduced T cells. These studies provided a portion of the experimental evidence supporting the feasibility of the presently ongoing clinical trials of lymphocyte gene therapy in cancer as well as in patients with adenosine deaminase deficiency.

Original languageEnglish (US)
Pages (from-to)3155-3159
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume88
Issue number8
StatePublished - 1991
Externally publishedYes

Fingerprint

Genetic Therapy
Lymphocytes
T-Lymphocytes
Neomycin
Tumor-Infiltrating Lymphocytes
Insertional Mutagenesis
Genes
Totipotent Stem Cells
Gene Expression
Antigens
Growth
Helper-Inducer T-Lymphocytes
Nude Mice
Interleukin-2
Cultured Cells
Spleen
Bone Marrow
Clinical Trials
Phenotype
Membranes

Keywords

  • Adenosine deaminase
  • Interleukin 2
  • Neomycin resistance
  • Retroviral vector
  • Tumor-infiltrating lymphocyte

ASJC Scopus subject areas

  • General
  • Genetics

Cite this

Culver, K., Cornetta, K., Morgan, R., Morecki, S., Aebersold, P., Kasid, A., ... Michael Blaese, R. (1991). Lymphocytes as cellular vehicles for gene therapy in mouse and man. Proceedings of the National Academy of Sciences of the United States of America, 88(8), 3155-3159.

Lymphocytes as cellular vehicles for gene therapy in mouse and man. / Culver, Kenneth; Cornetta, Kenneth; Morgan, Rick; Morecki, Shoshana; Aebersold, Paul; Kasid, Attan; Lotze, Michael; Rosenberg, Steven A.; French Anderson, W.; Michael Blaese, R.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 88, No. 8, 1991, p. 3155-3159.

Research output: Contribution to journalArticle

Culver, K, Cornetta, K, Morgan, R, Morecki, S, Aebersold, P, Kasid, A, Lotze, M, Rosenberg, SA, French Anderson, W & Michael Blaese, R 1991, 'Lymphocytes as cellular vehicles for gene therapy in mouse and man', Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 8, pp. 3155-3159.
Culver, Kenneth ; Cornetta, Kenneth ; Morgan, Rick ; Morecki, Shoshana ; Aebersold, Paul ; Kasid, Attan ; Lotze, Michael ; Rosenberg, Steven A. ; French Anderson, W. ; Michael Blaese, R. / Lymphocytes as cellular vehicles for gene therapy in mouse and man. In: Proceedings of the National Academy of Sciences of the United States of America. 1991 ; Vol. 88, No. 8. pp. 3155-3159.
@article{2698b895d86e4bae825746249550fe55,
title = "Lymphocytes as cellular vehicles for gene therapy in mouse and man",
abstract = "The application of bone marrow gene therapy has been stalled by the inability to achieve stable high-level gene transfer and expression in the totipotent stem cells. We show that retroviral vectors can stably introduce genes into antigen-specific murine and human T lymphocytes in culture. Murine helper T cells were transduced with the retroviral vector SAX to express both neomycin-resistance and human adenosine deaminase genes. These cells were expanded in culture and selected for expression of neomycin resistance with G418. The gene insertion, selection, and culture expansion did not alter antigen specificity or growth characteristics of the T cells in vitro. To determine if cultured T cells might be used for gene therapy, their persistence and continued expression of the introduced genes was evaluated in nude mice transplanted with the SAX-transduced T cells. G418-resistant cells could be readily recovered from the spleens of recipients of transduced T cells for several months. In addition, recovered cells continued to produce human adenosine deaminase. Based on these observations, we studied cultured human tumor-infiltrating lymphocytes as a candidate cell for a trial of gene transfer in man. Exponential cultures of interieukin-2-stimulated tumor-infiltrating lymphocytes were efficiently transduced with the neomycin-resistance gene using the retroviral vector N2. Gene insertion and subsequent G418 selection did not substantially alter the growth characteristics, interleukin 2 dependence, membrane phenotype, or cytotoxicity profile of the transduced T cells. These studies provided a portion of the experimental evidence supporting the feasibility of the presently ongoing clinical trials of lymphocyte gene therapy in cancer as well as in patients with adenosine deaminase deficiency.",
keywords = "Adenosine deaminase, Interleukin 2, Neomycin resistance, Retroviral vector, Tumor-infiltrating lymphocyte",
author = "Kenneth Culver and Kenneth Cornetta and Rick Morgan and Shoshana Morecki and Paul Aebersold and Attan Kasid and Michael Lotze and Rosenberg, {Steven A.} and {French Anderson}, W. and {Michael Blaese}, R.",
year = "1991",
language = "English (US)",
volume = "88",
pages = "3155--3159",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "8",

}

TY - JOUR

T1 - Lymphocytes as cellular vehicles for gene therapy in mouse and man

AU - Culver, Kenneth

AU - Cornetta, Kenneth

AU - Morgan, Rick

AU - Morecki, Shoshana

AU - Aebersold, Paul

AU - Kasid, Attan

AU - Lotze, Michael

AU - Rosenberg, Steven A.

AU - French Anderson, W.

AU - Michael Blaese, R.

PY - 1991

Y1 - 1991

N2 - The application of bone marrow gene therapy has been stalled by the inability to achieve stable high-level gene transfer and expression in the totipotent stem cells. We show that retroviral vectors can stably introduce genes into antigen-specific murine and human T lymphocytes in culture. Murine helper T cells were transduced with the retroviral vector SAX to express both neomycin-resistance and human adenosine deaminase genes. These cells were expanded in culture and selected for expression of neomycin resistance with G418. The gene insertion, selection, and culture expansion did not alter antigen specificity or growth characteristics of the T cells in vitro. To determine if cultured T cells might be used for gene therapy, their persistence and continued expression of the introduced genes was evaluated in nude mice transplanted with the SAX-transduced T cells. G418-resistant cells could be readily recovered from the spleens of recipients of transduced T cells for several months. In addition, recovered cells continued to produce human adenosine deaminase. Based on these observations, we studied cultured human tumor-infiltrating lymphocytes as a candidate cell for a trial of gene transfer in man. Exponential cultures of interieukin-2-stimulated tumor-infiltrating lymphocytes were efficiently transduced with the neomycin-resistance gene using the retroviral vector N2. Gene insertion and subsequent G418 selection did not substantially alter the growth characteristics, interleukin 2 dependence, membrane phenotype, or cytotoxicity profile of the transduced T cells. These studies provided a portion of the experimental evidence supporting the feasibility of the presently ongoing clinical trials of lymphocyte gene therapy in cancer as well as in patients with adenosine deaminase deficiency.

AB - The application of bone marrow gene therapy has been stalled by the inability to achieve stable high-level gene transfer and expression in the totipotent stem cells. We show that retroviral vectors can stably introduce genes into antigen-specific murine and human T lymphocytes in culture. Murine helper T cells were transduced with the retroviral vector SAX to express both neomycin-resistance and human adenosine deaminase genes. These cells were expanded in culture and selected for expression of neomycin resistance with G418. The gene insertion, selection, and culture expansion did not alter antigen specificity or growth characteristics of the T cells in vitro. To determine if cultured T cells might be used for gene therapy, their persistence and continued expression of the introduced genes was evaluated in nude mice transplanted with the SAX-transduced T cells. G418-resistant cells could be readily recovered from the spleens of recipients of transduced T cells for several months. In addition, recovered cells continued to produce human adenosine deaminase. Based on these observations, we studied cultured human tumor-infiltrating lymphocytes as a candidate cell for a trial of gene transfer in man. Exponential cultures of interieukin-2-stimulated tumor-infiltrating lymphocytes were efficiently transduced with the neomycin-resistance gene using the retroviral vector N2. Gene insertion and subsequent G418 selection did not substantially alter the growth characteristics, interleukin 2 dependence, membrane phenotype, or cytotoxicity profile of the transduced T cells. These studies provided a portion of the experimental evidence supporting the feasibility of the presently ongoing clinical trials of lymphocyte gene therapy in cancer as well as in patients with adenosine deaminase deficiency.

KW - Adenosine deaminase

KW - Interleukin 2

KW - Neomycin resistance

KW - Retroviral vector

KW - Tumor-infiltrating lymphocyte

UR - http://www.scopus.com/inward/record.url?scp=0026345422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026345422&partnerID=8YFLogxK

M3 - Article

C2 - 2014235

AN - SCOPUS:0026345422

VL - 88

SP - 3155

EP - 3159

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 8

ER -